Hormonal Contraception Not Linked to Idiopathic Intracranial Hypertension, Study Suggests
A comprehensive review of existing research indicates that hormonal contraception (HC) does not appear to be associated with an increased prevalence of idiopathic intracranial hypertension (IIH). This finding, published online on March 25, 2026, in the esteemed journal Neurology, offers a degree of reassurance to women considering or currently using various forms of hormonal birth control.
The study, a systematic review and meta-analysis conducted by researchers at the University of Toronto, aimed to meticulously examine the potential link between HC use and the occurrence of IIH. The team scoured medical literature to identify relevant observational studies that compared the usage of hormonal contraception among women diagnosed with IIH against a control group of women without the condition.
Key Findings from the Analysis:
- Overall Association: The review found no statistically significant association between the use of hormonal contraception and the prevalence of IIH. This suggests that women using HC are not demonstrably more likely to develop IIH than those who do not.
- Specific Contraceptive Methods: Further breakdown of the data into specific types of hormonal contraception also revealed no significant links. This included:
- Oral contraceptive pills
- Intrauterine devices (IUDs)
- Medroxyprogesterone acetate injections
- Robustness of Results: Sensitivity analyses were performed to test the reliability of the findings. These analyses largely confirmed the initial conclusions, indicating that the results were robust across different analytical approaches.
- Quality of Evidence: It is important to acknowledge the limitations of the current body of research. The quality assessments of the included studies varied significantly, ranging from poor to good. Consequently, the certainty of the evidence was deemed to be very low to low.
“Our findings can provide reassurance that using hormonal contraception may not be linked to this condition,” stated coauthor Dr. Arun N.E. Sundaram, also affiliated with the University of Toronto. He further emphasised the need for continued research, noting, “However, it is important to note that the evidence is limited and large, well-designed studies are needed, particularly in diverse patient groups, to confirm these results.”
Understanding Idiopathic Intracranial Hypertension (IIH)
Idiopathic intracranial hypertension, previously known as pseudotumor cerebri, is a neurological disorder characterised by increased pressure around the brain. This elevation in intracranial pressure occurs without a known cause, such as a tumour or other identifiable brain lesion. Symptoms can include severe headaches, visual disturbances (such as transient visual obscurations, blurred vision, or even vision loss), pulsatile tinnitus (a rhythmic whooshing sound in the ears), and sometimes double vision.
While the exact cause of IIH remains unclear, it is more common in women of childbearing age, and obesity is a significant risk factor. The condition can lead to permanent vision loss if not treated promptly. Treatment often involves weight loss, medications to reduce cerebrospinal fluid production, and in some severe cases, surgical interventions.
Implications for Healthcare Providers and Patients
The findings of this review are significant for both healthcare providers and women. For decades, there has been a degree of uncertainty and concern regarding a potential link between hormonal contraception and IIH, partly due to the demographic overlap between users of HC and those diagnosed with IIH. This study, by systematically analysing available data, helps to clarify this relationship.
However, the researchers are careful to highlight the limitations. The “very low to low certainty of evidence” means that while the current data does not suggest a link, more robust research is essential. Future studies should aim to:
- Increase Sample Sizes: Enrol larger numbers of participants to provide greater statistical power.
- Improve Study Design: Employ more rigorous study designs, such as prospective cohort studies, to better establish temporal relationships and minimise bias.
- Focus on Diverse Populations: Include participants from a wide range of ethnic backgrounds, ages, and socioeconomic statuses to ensure the findings are generalisable.
- Detailed HC Use Characterisation: Collect more granular data on the specific types, durations, and dosages of hormonal contraceptives used by participants.
Until more definitive evidence emerges, healthcare professionals should continue to counsel patients about the potential risks and benefits of all contraceptive methods, taking individual medical histories and risk factors into account. Women experiencing symptoms suggestive of IIH, regardless of their contraceptive use, should seek prompt medical attention for diagnosis and management.
One author involved in the review disclosed ties to Invex Therapeutics, GenSight, and Ocular Therapeutix.
